Virus induced genetic changes in the pathogenesis of autoimmune myositis
Virus induced genetic changes in the pathogenesis of autoimmune myositis
批准号:
9226076
负责人:
KANNEBOYINA NAGARAJU
金额:
$19.97万
依托单位国家:
美国
项目类别:
财政年份:
2017
资助国家:
美国
项目状态:
已结题
起止时间:
2017-01-01 至 2018-12-31
关键词:
AffectApoptosisAutoimmune ProcessBCL-2 ProteinBacteriaBiopsyC57BL/6 MouseCalciumCell DeathCell Death Signaling ProcessCellsCessation of lifeChronicComplexCoxsackie B VirusesDNA MethylationData SetDermatomyositisDiseaseEpigenetic ProcessEtiologyExposure toExtravasationFunctional disorderGene ExpressionGene Expression AlterationGene Expression ProfileGene Expression ProfilingGenesGeneticGenomeGenomicsHRK geneHomeostasisHumanIdiopathic Inflammatory MyopathiesImmune responseIn VitroInclusion Body MyositisIndividualInfectious AgentInfiltrationInflammationInflammatoryInjuryInterferon Type IMembraneMitochondriaMononuclearMusMuscleMuscle FatigueMuscle FibersMuscle WeaknessMuscular AtrophyMutationMyositisOnset of illnessParasitesPathogenesisPathogenicityPatientsPersonsPharmaceutical PreparationsPolymyositisProcessProtein FamilyRoleSkeletal MuscleTechniquesTestingTissuesTransgenic MiceUV Radiation ExposureViralViral GenomeVirusVirus Diseaseschronic autoimmune diseasedisease phenotypeenvironmental agentepigenomeexperimental studyimprovedin vivomembermitochondrial dysfunctionmouse modelmuscle degenerationrepaired
中文摘要
点击翻译按钮获取中文摘要
英文摘要
Abstract:
The etiology of idiopathic inflammatory myopathies is currently unknown. Temporal association of myositis
onset with environmental agents such as viruses in certain individuals suggests that specific exposure, in the
context of certain genetic backgrounds, can initiate muscle inflammation. Attempts to identify viruses in the
tissues of IIM patients by sensitive techniques such as PCR have failed, bringing into question the viral etiology
of these diseases and ruling out continual viral infection as a cause of the ongoing muscle inflammation in
these patients. However, the previous studies do not exclude the possibility that viruses may alter the
epigenome in affected cells and initiate pathogenic processes prior to their elimination by the host’s immune
response, thus explaining the absence of viral genomes and presence of type I interferon signature gene
expression in the myositis muscle tissue. Here we propose that it is unlikely that a unique environmental agent
initiates the myositis disease phenotype, but it is highly likely that a diverse group of common environmental
agents causes tissue specific epigenetic and gene expression alterations in cell homeostasis, survival and
death genes, resulting in the manifestation of the disease phenotype in persons with a susceptible genetic
background. There is also significant evidence that epigenetic changes at the genomic level could be
responsible for the pathogenesis of complex inflammatory diseases of unknown etiology. In preliminary in vitro
experiments, we found that Coxsackie B virus infection alters the DNA methylation and expression of genes
controlling membrane and cytoskeletal stability, cell death and apoptosis. Here we hypothesize that sustained
increased expression of HRK causes mitochondrial dysfunction that compromises sarcolemmal integrity,
leading to increased cytosolic calcium, membrane leakiness, cell death and inflammation, which enhance
muscle degeneration and wasting in myositis. Aim 1:To test whether changes in the expression of HRK alter
membrane repair and cell death signaling in vitro in human skeletal muscle, Aim 2:To determine whether
decreased expression of HRK in skeletal muscle improves muscle damage and weakness in myositis-prone
mice and Aim 3:To determine whether increased expression of HRK in skeletal muscle induces muscle
damage and weakness in myositis prone and wild-type (C57BL/6) mice. The proposed studies will help
elucidate the genetic basis for the disease phenotype, and their results may radically change our current
concepts on the role common environmental agents in initiating and sustaining chronic autoimmune diseases
such as myositis.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Dystrophin turnover after exon-skipping
-
批准号:9293874
-
项目类别:
-
资助金额:$39.0万
-
财政年份:2016
-
负责人:KANNEBOYINA NAGARAJU
-
依托单位:
Preclinical drug trial in mouse models of inflammation
-
批准号:8690993
-
项目类别:
-
资助金额:$10.62万
-
财政年份:2011
-
负责人:KANNEBOYINA NAGARAJU
-
依托单位:
Preclinical drug trial in mouse models of inflammation
-
批准号:8242218
-
项目类别:
-
资助金额:$10.62万
-
财政年份:2011
-
负责人:KANNEBOYINA NAGARAJU
-
依托单位:
Preclinical drug trial in mouse models of inflammation
-
批准号:8325061
-
项目类别:
-
资助金额:$10.62万
-
财政年份:2011
-
负责人:KANNEBOYINA NAGARAJU
-
依托单位:
Pathogenesis of autoimmune myositis: Role of MHC Class 1
-
批准号:7903812
-
项目类别:
-
资助金额:$22.43万
-
财政年份:2009
-
负责人:KANNEBOYINA NAGARAJU
-
依托单位:
Pathogenesis of autoimmune myositis: Role of MHC Class 1
-
批准号:7197328
-
项目类别:
-
资助金额:$34.63万
-
财政年份:2005
-
负责人:KANNEBOYINA NAGARAJU
-
依托单位:
Pathogenesis of autoimmune myositis: Role of MHC Class 1
-
批准号:7186420
-
项目类别:
-
资助金额:$21.9万
-
财政年份:2005
-
负责人:KANNEBOYINA NAGARAJU
-
依托单位:
Pathogenesis of autoimmune myositis: Role of MHC Class 1
-
批准号:7391060
-
项目类别:
-
资助金额:$33.94万
-
财政年份:2005
-
负责人:KANNEBOYINA NAGARAJU
-
依托单位:
Pathogenesis of autoimmune myositis: Role of MHC Class 1
-
批准号:6926751
-
项目类别:
-
资助金额:$9.98万
-
财政年份:2005
-
负责人:KANNEBOYINA NAGARAJU
-
依托单位:
Pathogenesis of autoimmune myositis: Role of MHC Class 1
-
批准号:7576722
-
项目类别:
-
资助金额:$33.94万
-
财政年份:2005
-
负责人:KANNEBOYINA NAGARAJU
-
依托单位:
Pathogenesis of autoimmune myositis: Role of MHC Class 1
-
批准号:7037612
-
项目类别:
-
资助金额:$35.66万
-
财政年份:2005
-
负责人:KANNEBOYINA NAGARAJU
-
依托单位:
Preclinical dosing optimization: Dosing schedule, tissue
-
批准号:8261239
-
项目类别:
-
资助金额:$17.89万
-
财政年份:--
-
负责人:KANNEBOYINA NAGARAJU
-
依托单位:
Preclinical dosing optimization: Dosing schedule, tissue
-
批准号:8883660
-
项目类别:
-
资助金额:$14.65万
-
财政年份:--
-
负责人:KANNEBOYINA NAGARAJU
-
依托单位:
In vitro and in vivo functional assays
-
批准号:8102470
-
项目类别:
-
资助金额:$28.49万
-
财政年份:--
-
负责人:KANNEBOYINA NAGARAJU
-
依托单位:
Preclinical dosing optimization: Dosing schedule, tissue
-
批准号:8380383
-
项目类别:
-
资助金额:$14.47万
-
财政年份:--
-
负责人:KANNEBOYINA NAGARAJU
-
依托单位:
Preclinical dosing optimization: Dosing schedule, tissue
-
批准号:8677926
-
项目类别:
-
资助金额:$14.18万
-
财政年份:--
-
负责人:KANNEBOYINA NAGARAJU
-
依托单位:
Preclinical dosing optimization: Dosing schedule, tissue
-
批准号:8472516
-
项目类别:
-
资助金额:$13.79万
-
财政年份:--
-
负责人:KANNEBOYINA NAGARAJU
-
依托单位:
国内基金
海外基金
登录
查看更多内容
Epac1/2通过蛋白酶体调控中性粒细胞NETosis和Apoptosis在急性肺损伤中的作用研究
-
批准号:LBY21H010001
-
项目类别:省市级项目
-
资助金额:--
-
批准年份:2020
-
负责人:郑绪阳
-
依托单位:
基于Apoptosis/Ferroptosis双重激活效应的天然产物AlbiziabiosideA的抗肿瘤作用机制研究及其结构改造
-
批准号:81703335
-
项目类别:青年科学基金项目
-
资助金额:20.0万元
-
批准年份:2017
-
负责人:卫高菲
-
依托单位:
双肝移植后Apoptosis和pyroptosis在移植物萎缩差异中的作用和供受者免疫微环境变化研究
-
批准号:81670594
-
项目类别:面上项目
-
资助金额:58.0万元
-
批准年份:2016
-
负责人:陈昊
-
依托单位:
Serp-2 调控apoptosis和pyroptosis 对肝脏缺血再灌注损伤的保护作用研究
-
批准号:81470791
-
项目类别:面上项目
-
资助金额:73.0万元
-
批准年份:2014
-
负责人:董家鸿
-
依托单位:
Apoptosis signal-regulating kinase 1是七氟烷抑制小胶质细胞活化的关键分子靶点?
-
批准号:81301123
-
项目类别:青年科学基金项目
-
资助金额:23.0万元
-
批准年份:2013
-
负责人:王海莲
-
依托单位:
APO-miR(multi-targeting apoptosis-regulatory miRNA)在前列腺癌中的表达和作用
-
批准号:81101529
-
项目类别:青年科学基金项目
-
资助金额:22.0万元
-
批准年份:2011
-
负责人:陈雪芹
-
依托单位:
放疗与细胞程序性死亡(APOPTOSIS)相关性及其应用研究
-
批准号:39500043
-
项目类别:青年科学基金项目
-
资助金额:9.0万元
-
批准年份:1995
-
负责人:梁克
-
依托单位: